PL1830888T3 - Kompleksy lipidowe pokryte PEG i ich wykorzystanie - Google Patents
Kompleksy lipidowe pokryte PEG i ich wykorzystanieInfo
- Publication number
- PL1830888T3 PL1830888T3 PL05822677T PL05822677T PL1830888T3 PL 1830888 T3 PL1830888 T3 PL 1830888T3 PL 05822677 T PL05822677 T PL 05822677T PL 05822677 T PL05822677 T PL 05822677T PL 1830888 T3 PL1830888 T3 PL 1830888T3
- Authority
- PL
- Poland
- Prior art keywords
- peg
- lipid complexes
- complexes coated
- coated
- lipid
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04030846 | 2004-12-27 | ||
| EP05822677.0A EP1830888B1 (en) | 2004-12-27 | 2005-12-27 | Lipid complexes coated with peg and their use |
| PCT/EP2005/014074 WO2006069782A2 (en) | 2004-12-27 | 2005-12-27 | Lipid complexes coated with peg and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1830888T3 true PL1830888T3 (pl) | 2015-12-31 |
Family
ID=36540272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05822677T PL1830888T3 (pl) | 2004-12-27 | 2005-12-27 | Kompleksy lipidowe pokryte PEG i ich wykorzystanie |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8852472B2 (enExample) |
| EP (2) | EP1830888B1 (enExample) |
| JP (1) | JP5292572B2 (enExample) |
| KR (1) | KR101366482B1 (enExample) |
| CN (1) | CN101287497B (enExample) |
| AU (1) | AU2005321469B2 (enExample) |
| BR (1) | BRPI0519468A2 (enExample) |
| CA (1) | CA2593032C (enExample) |
| DK (1) | DK1830888T3 (enExample) |
| ES (1) | ES2548515T3 (enExample) |
| HK (1) | HK1222541A1 (enExample) |
| IL (1) | IL183775A (enExample) |
| MX (1) | MX2007007913A (enExample) |
| PL (1) | PL1830888T3 (enExample) |
| SG (1) | SG158175A1 (enExample) |
| WO (1) | WO2006069782A2 (enExample) |
| ZA (1) | ZA200704168B (enExample) |
Families Citing this family (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| WO2006069782A2 (en) | 2004-12-27 | 2006-07-06 | Silence Therapeutics Ag. | Lipid complexes coated with peg and their use |
| CA2565633C (en) | 2004-05-05 | 2016-04-26 | Atugen Ag | Lipids, lipid complexes and use thereof |
| CA2607185A1 (en) * | 2005-05-04 | 2006-11-09 | Noxxon Pharma Ag | Intracellular active agents |
| ES2549728T3 (es) * | 2006-04-20 | 2015-11-02 | Silence Therapeutics Gmbh | Formulaciones de lipoplexo para la administración específica al endotelio vascular |
| CN101490253A (zh) * | 2006-07-21 | 2009-07-22 | 赛伦斯治疗公司 | 用于抑制蛋白激酶3表达的方法 |
| US8193246B2 (en) | 2006-12-19 | 2012-06-05 | Marina Biotech, Inc. | Lipids and lipid assemblies comprising transfection enhancer elements |
| WO2010021720A1 (en) | 2008-08-19 | 2010-02-25 | Nektar Therapeutics | Conjugates of small-interfering nucleic acids |
| JP2012517815A (ja) | 2009-02-18 | 2012-08-09 | サイレンス・セラピューティクス・アーゲー | Ａｎｇ２の発現を阻害するための手段 |
| WO2011035065A1 (en) | 2009-09-17 | 2011-03-24 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
| US8359883B2 (en) * | 2009-11-13 | 2013-01-29 | Hasmukh Dholakiya | Gemstone setting |
| WO2011120053A1 (en) | 2010-03-26 | 2011-09-29 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
| WO2012113413A1 (en) * | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| TW201726600A (zh) | 2012-07-06 | 2017-08-01 | 協和醱酵麒麟有限公司 | 陽離子性脂質 |
| WO2014018375A1 (en) | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
| ES2747762T3 (es) | 2013-08-21 | 2020-03-11 | Curevac Ag | Vacuna contra el virus respiratorio sincitial (RSV) |
| KR20160095003A (ko) * | 2013-12-05 | 2016-08-10 | 사일런스 테라퓨틱스 게엠베하 | 폐 특이적 전달을 위한 수단 |
| US10611664B2 (en) | 2014-07-31 | 2020-04-07 | Corning Incorporated | Thermally strengthened architectural glass and related systems and methods |
| US11097974B2 (en) | 2014-07-31 | 2021-08-24 | Corning Incorporated | Thermally strengthened consumer electronic glass and related systems and methods |
| WO2016083623A1 (en) * | 2014-11-28 | 2016-06-02 | Silence Therapeutics Gmbh | Means for the treatment of pre-eclampsia |
| US12338159B2 (en) | 2015-07-30 | 2025-06-24 | Corning Incorporated | Thermally strengthened consumer electronic glass and related systems and methods |
| JP6923555B2 (ja) | 2016-01-12 | 2021-08-18 | コーニング インコーポレイテッド | 薄厚熱強化及び化学強化ガラス系物品 |
| US11795102B2 (en) | 2016-01-26 | 2023-10-24 | Corning Incorporated | Non-contact coated glass and related coating system and method |
| CN106038517A (zh) * | 2016-03-14 | 2016-10-26 | 苏州博创康源生物技术有限公司 | 一种多糖药物载药组织粘贴膜及其制备方法 |
| CN105832709A (zh) * | 2016-03-14 | 2016-08-10 | 苏州博创康源生物技术有限公司 | 一种核酸药物载药组织粘贴膜及其制备方法 |
| CN106038516A (zh) * | 2016-03-14 | 2016-10-26 | 苏州博创康源生物技术有限公司 | 一种化合物药物载药组织粘贴膜及其制备方法 |
| CN105902523A (zh) * | 2016-03-14 | 2016-08-31 | 苏州博创康源生物技术有限公司 | 一种载药组织粘贴膜及其制备方法 |
| CN105687165A (zh) * | 2016-03-14 | 2016-06-22 | 苏州博创康源生物技术有限公司 | 一种蛋白或多肽药物载药组织粘贴膜及其制备方法 |
| US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2018035387A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| US12297436B2 (en) | 2017-05-18 | 2025-05-13 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| US11485673B2 (en) | 2017-08-24 | 2022-11-01 | Corning Incorporated | Glasses with improved tempering capabilities |
| KR102338449B1 (ko) | 2017-09-21 | 2021-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 |
| WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| TWI785156B (zh) | 2017-11-30 | 2022-12-01 | 美商康寧公司 | 具有高熱膨脹係數及對於熱回火之優先破裂行為的非離子交換玻璃 |
| US20230193242A1 (en) | 2017-12-22 | 2023-06-22 | The Broad Institute, Inc. | Cas12b systems, methods, and compositions for targeted dna base editing |
| US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
| EP3833761A1 (en) | 2018-08-07 | 2021-06-16 | The Broad Institute, Inc. | Novel cas12b enzymes and systems |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
| KR20210154825A (ko) | 2019-04-23 | 2021-12-21 | 코닝 인코포레이티드 | 확정 응력 프로파일을 갖는 유리 라미네이트 및 그 제조방법 |
| WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
| EP3999642A1 (en) | 2019-07-19 | 2022-05-25 | Flagship Pioneering Innovations VI, LLC | Recombinase compositions and methods of use |
| US11697617B2 (en) | 2019-08-06 | 2023-07-11 | Corning Incorporated | Glass laminate with buried stress spikes to arrest cracks and methods of making the same |
| JP2023520764A (ja) | 2020-03-24 | 2023-05-19 | ジェネレーション バイオ カンパニー | 第ｉｘ因子治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用 |
| MX2022011806A (es) | 2020-03-24 | 2023-01-11 | Generation Bio Co | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher. |
| IL298362A (en) | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Coronavirus antigen compositions and their uses |
| AU2021275213A1 (en) | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| AU2021281453A1 (en) | 2020-05-29 | 2022-11-17 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
| CA3180101A1 (en) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods relating thereto |
| WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| WO2022051629A1 (en) | 2020-09-03 | 2022-03-10 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| JP2024501288A (ja) | 2020-12-23 | 2024-01-11 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 修飾ｔｒｅｍの組成物及びその使用 |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| AU2022260111A1 (en) | 2021-04-20 | 2023-11-30 | Anjarium Biosciences Ag | Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof |
| AU2022264509A1 (en) | 2021-04-27 | 2023-12-14 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
| EP4329884A1 (en) | 2021-04-27 | 2024-03-06 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| CN113372226B (zh) * | 2021-06-08 | 2023-05-26 | 深圳市人民医院 | 一种脂质分子、脂质纳米粒及其制备方法和应用 |
| EP4377457A1 (en) | 2021-07-26 | 2024-06-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and uses thereof |
| EP4271818B1 (en) | 2021-09-17 | 2024-07-31 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for producing circular polyribonucleotides |
| TW202322826A (zh) | 2021-10-18 | 2023-06-16 | 美商旗艦先鋒創新有限責任公司 | 用於純化多核糖核苷酸之組成物及方法 |
| WO2023081526A1 (en) | 2021-11-08 | 2023-05-11 | Orna Therapeutics, Inc. | Lipid nanoparticle compositions for delivering circular polynucleotides |
| MX2024006440A (es) | 2021-11-24 | 2024-08-19 | Flagship Pioneering Innovations Vi Llc | Composiciones inmunogenicas y sus usos. |
| US20250352638A1 (en) | 2021-11-24 | 2025-11-20 | Flagship Pioneering Innovations Vi, Llc | Coronavirus immunogen compositions and their uses |
| CA3238370A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
| WO2023115013A1 (en) | 2021-12-17 | 2023-06-22 | Flagship Pioneering Innovations Vi, Llc | Methods for enrichment of circular rna under denaturing conditions |
| JP2025500360A (ja) | 2021-12-22 | 2025-01-09 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | ポリリボヌクレオチドを精製するための組成物及び方法 |
| IL313714A (en) | 2021-12-23 | 2024-08-01 | Flagship Pioneering Innovations Vi Llc | Cyclic polyribonucleotides encoding antifusogenic polypeptides |
| WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
| KR20240161965A (ko) | 2022-03-14 | 2024-11-13 | 제너레이션 바이오 컴퍼니 | 이종 프라임 부스트 백신 조성물 및 사용 방법 |
| CN119072464A (zh) | 2022-03-25 | 2024-12-03 | 赛欧生物医药股份有限公司 | 新型可电离脂质和脂质纳米颗粒以及其使用方法 |
| EP4503923A1 (en) | 2022-04-04 | 2025-02-12 | The Regents of the University of California | Genetic complementation compositions and methods |
| JP2025511756A (ja) | 2022-04-08 | 2025-04-16 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | ワクチン及び関連する方法 |
| WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| EP4522753A2 (en) | 2022-05-13 | 2025-03-19 | Flagship Pioneering Innovations VII, LLC | Double stranded dna compositions and related methods |
| EP4536197A1 (en) | 2022-06-07 | 2025-04-16 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| EP4544043A1 (en) | 2022-06-22 | 2025-04-30 | Flagship Pioneering Innovations VI, LLC | Compositions of modified trems and uses thereof |
| CN120129693A (zh) | 2022-08-01 | 2025-06-10 | 旗舰创业创新第七有限责任公司 | 免疫调节蛋白及相关方法 |
| EP4569112A1 (en) | 2022-08-12 | 2025-06-18 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
| WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| EP4581012A2 (en) | 2022-08-31 | 2025-07-09 | Sail Biomedicines, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| AU2023372397A1 (en) | 2022-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| EP4615465A1 (en) | 2022-11-08 | 2025-09-17 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for producing circular polyribonucleotides |
| WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| TW202425959A (zh) | 2022-11-08 | 2024-07-01 | 美商歐納醫療公司 | 遞送多核苷酸的脂質及奈米顆粒組合物 |
| TW202428289A (zh) | 2022-11-08 | 2024-07-16 | 美商歐納醫療公司 | 環狀rna組合物 |
| EP4626401A1 (en) | 2022-12-01 | 2025-10-08 | Generation Bio Co. | Stealth lipid nanoparticle compositions for cell targeting |
| AU2023406303A1 (en) | 2022-12-01 | 2025-05-29 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses |
| AU2023406321A1 (en) | 2022-12-01 | 2025-05-29 | Generation Bio Co. | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
| EP4626402A1 (en) | 2022-12-01 | 2025-10-08 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
| WO2024151673A2 (en) | 2023-01-09 | 2024-07-18 | President And Fellows Of Harvard College | Recombinant nucleic acid molecules and their use in wound healing |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| TW202438673A (zh) | 2023-01-09 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 疫苗及相關方法 |
| TW202438515A (zh) | 2023-02-06 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫調節組合物及相關方法 |
| US20240293318A1 (en) | 2023-02-13 | 2024-09-05 | Flagship Pioneering Innovations Vii, Llc | Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions |
| US20240293582A1 (en) | 2023-02-17 | 2024-09-05 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified cytosine |
| IL322201A (en) | 2023-02-17 | 2025-09-01 | Flagship Pioneering Innovations Vii Llc | DNA structures containing modified uracil |
| WO2024192422A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| KR20250162610A (ko) | 2023-03-15 | 2025-11-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도 |
| WO2024205657A2 (en) | 2023-03-29 | 2024-10-03 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| AU2024255972A1 (en) | 2023-04-12 | 2025-10-23 | Flagship Pioneering Innovations Vi, Llc | Modified trems, compositions, and related methods thereof |
| AU2024252590A1 (en) | 2023-04-12 | 2025-10-23 | Flagship Pioneering Innovations Vi, Llc | Trems for use in correction of missense mutations |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| WO2024233308A2 (en) | 2023-05-05 | 2024-11-14 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025006684A1 (en) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| WO2025024486A2 (en) | 2023-07-25 | 2025-01-30 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025049690A1 (en) | 2023-08-29 | 2025-03-06 | Orna Therapeutics, Inc. | Circular polyethylene glycol lipids |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025052180A2 (en) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2025064475A2 (en) | 2023-09-18 | 2025-03-27 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
| WO2025072383A1 (en) | 2023-09-25 | 2025-04-03 | The Broad Institute, Inc. | Viral open reading frames, uses thereof, and methods of detecting the same |
| WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025096807A2 (en) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025101501A1 (en) | 2023-11-07 | 2025-05-15 | Orna Therapeutics, Inc. | Circular rna compositions |
| TW202535835A (zh) | 2023-11-14 | 2025-09-16 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 可電離類脂質組成物及其治療用途 |
| TW202523695A (zh) | 2023-11-22 | 2025-06-16 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於治療非酒精性脂肪性肝病之方法及組成物 |
| WO2025117877A2 (en) | 2023-12-01 | 2025-06-05 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025129158A1 (en) | 2023-12-15 | 2025-06-19 | The Broad Institute, Inc. | Engineered arc delivery vesicles and uses thereof |
| US20250375499A1 (en) | 2024-01-26 | 2025-12-11 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025194019A1 (en) | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Methods for treating liver fibrosis and non-alcoholic fatty liver disease |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
| US20250353881A1 (en) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025245188A2 (en) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Methods of treating liver steatosis and non-alcoholic fatty liver disease |
| WO2025245111A1 (en) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor targeting proteins and related methods |
| WO2025242231A1 (en) * | 2024-05-24 | 2025-11-27 | Ribox Therapeutics Hk Limited | Cationic lipids and preparation method thereof |
| WO2025250808A1 (en) | 2024-05-29 | 2025-12-04 | The Brigham And Women’S Hospital, Inc. | Anti-crispr delivery compositions and methods |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
| GB2270920B (en) | 1992-09-25 | 1997-04-02 | Univ Keele | Alginate-bioactive agent conjugates |
| FR2698628B1 (fr) | 1992-12-02 | 1995-02-17 | Fournier Ind & Sante | Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique. |
| US5504103A (en) | 1993-08-25 | 1996-04-02 | Eli Lilly And Company | Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof |
| US5777153A (en) | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
| US5885613A (en) * | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| DE69634084T2 (de) | 1995-06-07 | 2005-12-08 | Inex Pharmaceuticals Corp. | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
| US7422902B1 (en) * | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| AU707947B2 (en) | 1995-07-21 | 1999-07-22 | Promega Biosciences, Inc. | Novel amide-based cationic lipids |
| JP2001504448A (ja) | 1996-08-30 | 2001-04-03 | フュルステ，イェンス，ペーター | 核酸の鏡面対称選択および進化 |
| US6958239B2 (en) | 1996-11-21 | 2005-10-25 | Oligos Etc Inc. | Three component chimeric antisense oligonucleotides |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| CA2217550A1 (en) | 1996-10-22 | 1998-04-22 | F. Hoffmann-La Roche Ag | Cationic lipids for gene therapy |
| US6358523B1 (en) | 1996-12-06 | 2002-03-19 | The Regents Of The University Of California | Macromolecule-lipid complexes and methods for making and regulating |
| AU6949098A (en) | 1997-04-04 | 1998-10-30 | Valentis, Inc. | Improved methods of delivery using cationic lipids and helper lipids |
| AU7490098A (en) | 1997-05-15 | 1998-12-08 | Genzyme Corporation | Cationic amphiphile formulations |
| AR012894A1 (es) | 1997-06-13 | 2000-11-22 | Lilly Co Eli | Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma. |
| US20030073640A1 (en) * | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| CA2301166A1 (en) * | 1997-07-24 | 1999-02-04 | Yuan-Peng Zhang | Liposomal compositions for the delivery of nucleic acid catalysts |
| US6150345A (en) | 1998-08-10 | 2000-11-21 | Regents Of The University Of California | Methods for promoting survival of myelin producing cells |
| FR2788275B1 (fr) | 1999-01-11 | 2002-06-14 | Lipha | ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7015040B2 (en) * | 1999-02-26 | 2006-03-21 | Mirus Bio Corporation | Intravascular delivery of nucleic acid |
| JP2003501038A (ja) | 1999-05-28 | 2003-01-14 | スージェン・インコーポレーテッド | 蛋白質キナーゼ |
| EP1064944A1 (en) | 1999-06-25 | 2001-01-03 | Schering Aktiengesellschaft | Protein kinase N inhibitor comprising Fasudil |
| AU771706B2 (en) * | 1999-07-15 | 2004-04-01 | University Of British Columbia, The | Methods and apparatus for preparation of lipid vesicles |
| US6133032A (en) | 1999-09-09 | 2000-10-17 | Isis Pharmaceutical Inc. | Antisense modulation of PI3 kinase p110 beta expression |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| CA2403962C (en) | 2000-03-31 | 2009-12-15 | Kirin Beer Kabushiki Kaisha | Powdery preparation for transmucosal administration comprising a medicine of high molecular weight and exhibiting an improved storage stability |
| JP2004508012A (ja) * | 2000-04-20 | 2004-03-18 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法 |
| AU2002214854A1 (en) * | 2000-10-25 | 2002-05-06 | Inex Pharmaceuticals Corporation | Lipid formulations for target delivery |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| US20030135033A1 (en) | 2002-01-04 | 2003-07-17 | Anke Klippel-Giese | Compounds and methods for the identification and/ or validation of a target |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| WO2004012680A2 (en) | 2002-08-06 | 2004-02-12 | Lyotropic Therapeutics, Inc. | Lipid-drug complexes in reversed liquid and liquid crystalline phases |
| CN1674929B (zh) | 2002-08-14 | 2013-07-17 | 赛伦斯治疗公司 | 蛋白激酶Nβ的应用 |
| EP1393742A1 (en) | 2002-08-14 | 2004-03-03 | atugen AG | Use of protein kinase N beta |
| US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
| EP2474630B1 (en) | 2002-12-20 | 2016-04-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2007503514A (ja) * | 2003-08-26 | 2007-02-22 | スミスクライン・ビーチャム・コーポレイション | グリセロールおよびポリエチレングリコールのヘテロ官能性コポリマー、そのコンジュゲートおよび組成物 |
| WO2006069782A2 (en) | 2004-12-27 | 2006-07-06 | Silence Therapeutics Ag. | Lipid complexes coated with peg and their use |
| CA2565633C (en) | 2004-05-05 | 2016-04-26 | Atugen Ag | Lipids, lipid complexes and use thereof |
| KR20070085232A (ko) | 2004-08-20 | 2007-08-27 | 더 존스 홉킨스 유니버시티 | 혈관신생 치료방법 |
| JP2008520600A (ja) | 2004-11-19 | 2008-06-19 | ノヴォソム アクチェンゲゼルシャフト | 局所投与のための医薬組成物におけるまたはそれに関する改善 |
| WO2006074546A1 (en) | 2005-01-13 | 2006-07-20 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| CA2649020A1 (en) | 2006-04-20 | 2007-11-01 | Silence Therapeutics Ag | Means for inhibiting the expression of cd31 |
| ES2549728T3 (es) | 2006-04-20 | 2015-11-02 | Silence Therapeutics Gmbh | Formulaciones de lipoplexo para la administración específica al endotelio vascular |
| CN101490253A (zh) | 2006-07-21 | 2009-07-22 | 赛伦斯治疗公司 | 用于抑制蛋白激酶3表达的方法 |
-
2005
- 2005-12-27 WO PCT/EP2005/014074 patent/WO2006069782A2/en not_active Ceased
- 2005-12-27 US US11/722,948 patent/US8852472B2/en not_active Expired - Fee Related
- 2005-12-27 ES ES05822677.0T patent/ES2548515T3/es active Active
- 2005-12-27 DK DK05822677.0T patent/DK1830888T3/en active
- 2005-12-27 SG SG200908620-8A patent/SG158175A1/en unknown
- 2005-12-27 KR KR1020077014611A patent/KR101366482B1/ko not_active Expired - Fee Related
- 2005-12-27 AU AU2005321469A patent/AU2005321469B2/en not_active Ceased
- 2005-12-27 EP EP05822677.0A patent/EP1830888B1/en not_active Not-in-force
- 2005-12-27 JP JP2007548751A patent/JP5292572B2/ja not_active Expired - Fee Related
- 2005-12-27 MX MX2007007913A patent/MX2007007913A/es active IP Right Grant
- 2005-12-27 PL PL05822677T patent/PL1830888T3/pl unknown
- 2005-12-27 EP EP15179144.9A patent/EP2992902A1/en not_active Withdrawn
- 2005-12-27 CA CA2593032A patent/CA2593032C/en not_active Expired - Fee Related
- 2005-12-27 CN CN2005800450816A patent/CN101287497B/zh not_active Expired - Fee Related
- 2005-12-27 BR BRPI0519468-7A patent/BRPI0519468A2/pt active Search and Examination
-
2007
- 2007-05-22 ZA ZA200704168A patent/ZA200704168B/en unknown
- 2007-06-07 IL IL183775A patent/IL183775A/en not_active IP Right Cessation
-
2014
- 2014-10-06 US US14/507,045 patent/US9387262B2/en not_active Expired - Fee Related
-
2016
- 2016-09-07 HK HK16110655.7A patent/HK1222541A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2548515T3 (es) | 2015-10-19 |
| CN101287497A (zh) | 2008-10-15 |
| KR20070090956A (ko) | 2007-09-06 |
| AU2005321469B2 (en) | 2012-04-05 |
| KR101366482B1 (ko) | 2014-02-21 |
| IL183775A (en) | 2016-12-29 |
| ZA200704168B (en) | 2008-05-28 |
| DK1830888T3 (en) | 2015-10-19 |
| BRPI0519468A2 (pt) | 2009-01-27 |
| US8852472B2 (en) | 2014-10-07 |
| WO2006069782A9 (en) | 2009-04-30 |
| EP1830888B1 (en) | 2015-08-05 |
| CA2593032A1 (en) | 2006-07-06 |
| IL183775A0 (en) | 2007-09-20 |
| SG158175A1 (en) | 2010-01-29 |
| WO2006069782A3 (en) | 2007-04-12 |
| EP1830888A2 (en) | 2007-09-12 |
| US20100062967A1 (en) | 2010-03-11 |
| HK1119090A1 (en) | 2009-02-27 |
| JP2008525514A (ja) | 2008-07-17 |
| AU2005321469A1 (en) | 2006-07-06 |
| US20150031752A1 (en) | 2015-01-29 |
| EP2992902A1 (en) | 2016-03-09 |
| CN101287497B (zh) | 2013-03-06 |
| JP5292572B2 (ja) | 2013-09-18 |
| US9387262B2 (en) | 2016-07-12 |
| MX2007007913A (es) | 2007-08-14 |
| HK1222541A1 (en) | 2017-07-07 |
| CA2593032C (en) | 2015-12-22 |
| WO2006069782A2 (en) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1830888T3 (pl) | Kompleksy lipidowe pokryte PEG i ich wykorzystanie | |
| IL178879A0 (en) | Lipids, lipid complexes and use thereof | |
| IL218117A (en) | A tablet containing saxagliptin and several layers of coating | |
| PL2287195T3 (pl) | Przeciwciała pan-kir2dl receptora nk i ich zastosowanie w diagnostyce i terapii | |
| IL183180A0 (en) | 1-alkynyl-2-aryloxyalkylamides and their use as fungicides | |
| IL181670A0 (en) | Substituted phenylaminothiazoles and use thereof | |
| IL183929A0 (en) | Use of inerferon - ?? in the preparation of a medicament | |
| IL189252A0 (en) | Dihydroxyanthraquinones and their use | |
| GB0407836D0 (en) | Fluorescent dyes and complexes | |
| PL2215908T3 (pl) | 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów | |
| GB0426903D0 (en) | Complexes and methods | |
| GB0411257D0 (en) | Cassette and its use | |
| FI20045309L (fi) | Menetelmä ja sovitelma päällystyslinjassa | |
| GB0515322D0 (en) | Ligands and use thereof | |
| GB0608797D0 (en) | Novel agents and the use thereof | |
| GB0409654D0 (en) | Its all in the name | |
| GB0410830D0 (en) | Compounds and their use | |
| GB0402903D0 (en) | Compounds and their use | |
| GB0410832D0 (en) | Compounds and their use | |
| GB0410833D0 (en) | Compounds and their use | |
| GB0411071D0 (en) | Compounds and their use | |
| GB0416630D0 (en) | Compounds and their use | |
| GB0403953D0 (en) | Compounds and their use | |
| GB0410831D0 (en) | Compounds and their use | |
| GB0410114D0 (en) | Compounds and their use |